HCV Treatment
8. More Treatment Options for More Types of HCV
- Details
- Category: HCV Treatment
- Published on Thursday, 22 December 2016 00:00
- Written by HIVandHepatitis.com
This year saw the approval of new highly effective direct-acting antiviral therapies for hepatitis C, with more in the pipeline and due for approval in 2017.
9. Primary Care Providers Can Treat Hepatitis C
- Details
- Category: HCV Treatment
- Published on Thursday, 22 December 2016 00:00
- Written by HIVandHepatitis.com
Interferon-free direct-acting antiviral therapy for hepatitis C is effective and simple enough that care can be managed by primary care providers, helping relieve the shortage of liver disease specialists.
AASLD 2016: Generic Sofosbuvir Underperforms in Real World, May Be Due to Suboptimal Regimens
- Details
- Category: HCV Treatment
- Published on Thursday, 15 December 2016 00:00
- Written by Michael Carter
Generic sofosbuvir-based combinations for hepatitis C may not perform as well as branded sofosbuvir-containing regimens, according to a study conducted in Qatar and presented at the recent 2016 AASLD Liver Meeting. People treated with generics were less likely to be cured and more likely to experience adverse events compared to people who received branded drugs. But the investigators speculate that the generics may have underperformed because many people treated were with suboptimal regimens, and believe this deserves further research.
AASLD 2016: Real-World Studies Show 8 Weeks of Sofosbuvir/Ledipasvir Equals 12 Weeks for Many Patients
- Details
- Category: HCV Treatment
- Published on Thursday, 15 December 2016 00:00
- Written by Keith Alcorn
An 8-week course of treatment with sofosbuvir/ledipasvir (Harvoni) is just as effective as a 12-week course for people with hepatitis C virus (HCV) genotype 1 without cirrhosis, including those with HIV/HCV coinfection, and could significantly reduce the cost of treatment if it was prescribed more widely, according to several large real-life cohort studies presented the 2016 AASLD Liver Meeting last month in Boston.
AASLD 2016: Glecaprevir/ Pibrentasvir Effective for Hepatitis C Patients with Severe Kidney Disease
- Details
- Category: HCV Treatment
- Published on Thursday, 15 December 2016 00:00
- Written by Liz Highleyman
A 2-drug pangenotypic regimen combining AbbVie's glecaprevir and pibrentasvir demonstrated a high sustained response rate for chronic hepatitis C patients with severe kidney impairment, according to results from the EXPEDITION-4 study presented at the 2016 AASLD Liver Meeting last month in Boston.
More Articles...
- AASLD 2016: Curing Hepatitis C May Help Reduce Kidney Disease Progression
- AASLD 2016: 6 Weeks of Sofosbuvir/Ledipasvir Cures Genotype 1 Acute Hepatitis C
- AASLD 2016: Non-Adherence Is Most Important Risk Factor for Sofosbuvir/Ledipasvir Failure
- AASLD 2016: Primary Care Providers Can Effectively Treat Patients with Hepatitis C
Web Design and Development by